CompletedPhase 1

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

A Randomized, Double-Blind, Placebo and Comparator-Controlled Crossover Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

Lead sponsor

Carmot Therapeutics, Inc.

Assets

CT-868 / Liraglutide

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight, Type 1 diabetes

Eligibility highlights

•BMI 25-35

Primary endpoint

•Area under the curve (AUC) in glucose metabolism during MMTT

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05794581

Org study IDCT-868-005

Timeline

Milestones

Study start2023-03-21actual

Study first posted2023-04-03actual

Primary completion2024-03-06actual

Study completion2024-04-06actual

Last update posted2024-12-27actual

Assets

Investigational agents

CT-868 Liraglutide

Who this study enrolls

Obesity / overweightType 1 diabetes

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Female or male adults with Type 1 diabetes

•Ages 18-65 years

•Type 1 DM for at least 3 years

•Using an insulin pump or multiple daily injections (MDI) for at least 3 months

•BMI 25.0 - 35.0

Exclusion criteria

•Significant medical history

•Uncontrolled diabetes

•History of surgical treatment for weight loss

•History of malignancy

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Safety / tolerability / PK

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

To assess area under the curve (AUC) in glucose metabolism during MMTT

Time frame:Baseline up to 4 days

descriptive

Secondary/protocol endpoint/low confidence

To assess changes in continuous glucose monitoring (CGM) measures

Time frame:Baseline up to 4 days

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Area under the acetaminophen concentration-time (AUC)

Time frame:0 - 300 minutes

AUC₀-∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.